» Articles » PMID: 12813914

Immune Evasion by Herpes Simplex Virus Type 1, Strategies for Virus Survival

Overview
Date 2003 Jun 20
PMID 12813914
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Many viruses capable of persistent or recurrent infections have evolved strategies to evade host immunity. Viral evasion molecules target components of innate and acquired immunity, including complement proteins, natural killer cells, MHC Class I or Class II molecules and antibody. Our work focuses on HSV-1 glycoproteins gC and gE that impair antibody and complement responses. gC inhibits complement activation by binding C3b and blocking activities mediated by this pivotal complement protein, while gE binds the IgG Fc domain, blocking Fc-mediated activities, including complement activation and antibody-dependent cellular cytotoxicity. HSV-1 mutant viruses that lack the ability to bind C3b, IgG Fc, or both are much less virulent than wild-type virus in a murine model. These HSV-1 immunoevasins help explain the virus' ability to produce recurrent infections despite intact immunity. Strategies to prevent immune evasion may be required to develop successful HSV vaccines.

Citing Articles

Improving antibody-mediated protection against HSV infection by eliminating interactions with the viral Fc receptor gE/gI.

Slein M, Backes I, Kelkar N, Garland C, Khanwalkar U, Sholukh A bioRxiv. 2024; .

PMID: 39605495 PMC: 11601663. DOI: 10.1101/2024.11.20.624598.


Fraternal Twins: The Enigmatic Role of the Immune System in Alphaherpesvirus Pathogenesis and Latency and Its Impacts on Vaccine Efficacy.

Rouse B, Schmid D Viruses. 2022; 14(5).

PMID: 35632603 PMC: 9147900. DOI: 10.3390/v14050862.


An mRNA vaccine to prevent genital herpes.

Awasthi S, Friedman H Transl Res. 2021; 242:56-65.

PMID: 34954087 PMC: 8695322. DOI: 10.1016/j.trsl.2021.12.006.


Stunning symmetries involved in the self-assembly of the HSV-1 capsid.

Lee J, Shim J, Kim S J Korean Phys Soc. 2021; 78(5):357-364.

PMID: 33584000 PMC: 7871024. DOI: 10.1007/s40042-020-00044-4.


Antiviral anticoagulation.

Pryzdial E, Sutherland M, Lin B, Horwitz M Res Pract Thromb Haemost. 2020; 4(5):774-788.

PMID: 32685886 PMC: 7354393. DOI: 10.1002/rth2.12406.


References
1.
Lubinski J, Wang L, Mastellos D, Sahu A, Lambris J, Friedman H . In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J Exp Med. 1999; 190(11):1637-46. PMC: 2195732. DOI: 10.1084/jem.190.11.1637. View

2.
Tomazin R, Boname J, Hegde N, Lewinsohn D, Altschuler Y, Jones T . Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med. 1999; 5(9):1039-43. DOI: 10.1038/12478. View

3.
Ishido S, Choi J, Lee B, Wang C, Demaria M, Johnson R . Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity. 2000; 13(3):365-74. DOI: 10.1016/s1074-7613(00)00036-4. View

4.
Lubinski J, Jiang M, Hook L, Chang Y, Sarver C, Mastellos D . Herpes simplex virus type 1 evades the effects of antibody and complement in vivo. J Virol. 2002; 76(18):9232-41. PMC: 136467. DOI: 10.1128/jvi.76.18.9232-9241.2002. View

5.
Friedman H, Cohen G, Eisenberg R, Seidel C, Cines D . Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature. 1984; 309(5969):633-5. DOI: 10.1038/309633a0. View